
Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent …

Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive …
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ

